AURELIA - the first randomized phase III trial of bevacizumab with standard chemotherapy in platinum-resistant ovarian cancer

Speaking on behalf of the AURELIA investigators (European ovarian cancer research groups), Dr Eric Pujade-Lauraine presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (1 - 5 June 2012) results from the first phase III trial combining bevacizumab with current standard of care - chemotherapy in the treatment of platinum-resistant recurrent ovarian cancer. This study is the first randomized phase III trial to demonstrate benefit with biologic therapy and benefit with combination therapy, rather than monotherapy, in patients with platinum-resistant ovarian cancer. The researchers concluded that bevacizumab combined with chemotherapy should be considered as a new standard of care. Read the news article here.